219 related articles for article (PubMed ID: 33831421)
1. GC-MS-based metabolomics reveals new biomarkers to assist the differentiation of prostate cancer and benign prostatic hyperplasia.
Wang W; He Z; Kong Y; Liu Z; Gong L
Clin Chim Acta; 2021 Aug; 519():10-17. PubMed ID: 33831421
[TBL] [Abstract][Full Text] [Related]
2. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
3. Serum organic acid metabolites can be used as potential biomarkers to identify prostatitis, benign prostatic hyperplasia, and prostate cancer.
He J; Han Z; Luo W; Shen J; Xie F; Liao L; Zou G; Luo X; Guo Z; Li Y; Li J; Chen H
Front Immunol; 2022; 13():998447. PubMed ID: 36685547
[TBL] [Abstract][Full Text] [Related]
4. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
5. Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone.
Xu B; Chen Y; Chen X; Gan L; Zhang Y; Feng J; Yu L
Front Oncol; 2021; 11():730638. PubMed ID: 34722271
[TBL] [Abstract][Full Text] [Related]
6. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
7. Circulating miRNAs as Biomarkers for Prostate Cancer Diagnosis in Subjects with Benign Prostatic Hyperplasia.
Jin W; Fei X; Wang X; Chen F; Song Y
J Immunol Res; 2020; 2020():5873056. PubMed ID: 32455140
[TBL] [Abstract][Full Text] [Related]
8. Using Genetic and Epigenetic Markers to Improve Differential Diagnosis of Prostate Cancer and Benign Prostatic Hyperplasia by Noninvasive Methods in Mexican Patients.
Sánchez BE; Aguayo A; Martínez B; Rodríguez F; Marmolejo M; Svyryd Y; Luna L; Muñoz LA; Jiménez MA; Sotomayor M; Vargas V F; Mutchinick OM
Clin Genitourin Cancer; 2018 Aug; 16(4):e867-e877. PubMed ID: 29571584
[TBL] [Abstract][Full Text] [Related]
9. CHRDL1, NEFH, TAGLN and SYNM as novel diagnostic biomarkers of benign prostatic hyperplasia and prostate cancer.
Su Z; Wang G; Li L
Cancer Biomark; 2023; 38(2):143-159. PubMed ID: 37781794
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
[TBL] [Abstract][Full Text] [Related]
11. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
[TBL] [Abstract][Full Text] [Related]
12. Metabolic markers in blood can separate prostate cancer from benign prostatic hyperplasia.
Giskeødegård GF; Hansen AF; Bertilsson H; Gonzalez SV; Kristiansen KA; Bruheim P; Mjøs SA; Angelsen A; Bathen TF; Tessem MB
Br J Cancer; 2015 Dec; 113(12):1712-9. PubMed ID: 26633561
[TBL] [Abstract][Full Text] [Related]
13. Oxidised low-density lipoprotein, a possible distinguishing lipid profile biomolecule between prostate cancer and benign prostatic hyperplasia.
Asare GA; Owusu-Boateng E; Asiedu B; Amoah BY; Essendoh E; Otoo RY
Andrologia; 2019 Sep; 51(8):e13321. PubMed ID: 31145504
[TBL] [Abstract][Full Text] [Related]
14. Percentage of free serum prostate-specific antigen: a new tool in the early diagnosis of prostatic cancer.
Toubert ME; Guillet J; Chiron M; Meria P; Role C; Schlageter MH; Francois H; Borschneck C; Nivelon F; Desgrandchamps F; Rastel D; Cussenot O; Teillac P; Le Duc A; Najean Y
Eur J Cancer; 1996 Nov; 32A(12):2088-93. PubMed ID: 9014750
[TBL] [Abstract][Full Text] [Related]
15. A novel urinary mRNA signature using the droplet digital polymerase chain reaction platform improves discrimination between prostate cancer and benign prostatic hyperplasia within the prostate-specific antigen gray zone.
Kang HW; Lee HY; Byun YJ; Jeong P; Yoon JS; Kim DH; Kim WT; Kim YJ; Lee SC; Yun SJ; Kim WJ
Investig Clin Urol; 2020 Jul; 61(4):411-418. PubMed ID: 32665998
[TBL] [Abstract][Full Text] [Related]
16. Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer.
Li J; Ren S; Piao HL; Wang F; Yin P; Xu C; Lu X; Ye G; Shao Y; Yan M; Zhao X; Sun Y; Xu G
Sci Rep; 2016 Feb; 6():20984. PubMed ID: 26865432
[TBL] [Abstract][Full Text] [Related]
17. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of PSAD and PSAD-TZ value in prostatic hyperplasia and prostatic cancer].
Fu Q; Yao DH; Jiang YQ
Zhonghua Nan Ke Xue; 2002 Dec; 8(6):411-3. PubMed ID: 12593013
[TBL] [Abstract][Full Text] [Related]
19. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract][Full Text] [Related]
20. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms--What has to be considered?
Jung K; Stephan C; Lein M; Brux B; Sinha P; Schnorr D; Loening SA
Prostate; 2001 Mar; 46(4):307-10. PubMed ID: 11241553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
